Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics

Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

November 13, 2024

Biotechnology

Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.; Peak Bio to List on NASDAQ

November 2, 2022

Biotechnology

Ignyte Acquisition Corp. completed a business combination with Peak Bio Co., Ltd., resulting in the combined company operating as Peak Bio, Inc. and commencing trading on NASDAQ under the ticker symbols PKBO (common stock) and PKBOW (warrants). The transaction positions Peak Bio to access public markets and raise capital to advance its oncology and inflammatory disease therapeutics, with Hoyoung Huh as Chairman and Stephen LaMond as COO.

Murphy Canyon Acquisition Corp. Completes Business Combination with Conduit Pharmaceuticals

September 22, 2023

Pharmaceuticals

Murphy Canyon Acquisition Corp. (MURF) completed its previously announced business combination with Conduit Pharmaceuticals Limited, resulting in the combined company trading on Nasdaq under the ticker CDT and a pro forma enterprise value of approximately $720 million. A single institutional investor purchased $20.0 million of MURF units in a private placement, and the combined transaction and offering provided Conduit with roughly $20 million of cash (after redemptions, before transaction expenses).